Prostate cancer topics, links and more. Now at 100+ posts!

News: Health Day, Medical News Today, ScienceDaily, Urol Times, Urotoday, Zero Cancer Papers: Pubmed (all), Pubmed (Free only), Amedeo
Journals: Eur Urol, J Urol, JCO, The Prostate Others Pubmed Central Journals (Free): Adv Urol, BMC Urol, J Endourol, Kor J Urol, Rev Urol, Ther Adv Urol, Urol Ann
Reviews: Cochrane Summaries, PC Infolink Newsletters: PCRI, US Too General Medical Reviews: f1000, Health News Review
Loading...

Monday, March 19, 2007

DCA

[Updated October 18, 2008]

DCA has been used in humans for 30 years but was only recently discovered to have anti-cancer properties (in mice). It works via a novel mechanism that would presumably apply to a broad range of cancers. The U of Alberta, where its potential use as an anti-cancer agent was discovered by a cardiologist, Dr.Michelakis, has set up a web page which has a letter from Dr. Michaelakis, Frequently Asked Questions (FAQ) and links to the substantial media coverage that this has garnered:
http://www.depmed.ualberta.ca/dca/
since publishing the work in Cancer Cell: [PMID: 17222789]

Self-medicating cancer patients have banded together to set up an online web site to share information on it as discussed in this news flash:
http://www.bcma.org/Newsflash/March19-2007.htm#3
Their web site is http://www.thedcasite.com/ and it includes a discussion forum. One person said his PSA doubled 20 days after taking DCA and there is further discussion of whether this could be a PSA bounce in response to dying cancer cells or whether it means it did not work. See:
http://www.thedcasite.com/cgi/dcboard.cgi?az=read_count&om=16&forum=DCForumID2

Although some of the comments from self medicating users on the web site are not encouraging some recent work at the University of Florida published in May 2008 supports the role of DCA as acting against bcl-2. As discussed in our post on post on Testosterone Metabolism bcl-2 protects cancer cells and therefore agents that act against bcl-2 might render the cancer defensiveless against attack by other drugs. Thus it might be that a more professional approach, such as in the upcoming clinical trial, could still work.

There is a September 2008 review of DCA [PMID: 18766181] by Michelakis.

Also on the DCA is site is information on Nobuto Yamamoto who has done work on DCA
as well as GcMAF. The latter seems promising based on small scale testing.
See Yamamoto file.

1 comment:

The Palpable Prostate said...

In this post on thedcasite one person trying DCA details his problems with neuropathy (a side effect).